{
  "schemaVersion": "orion-company-promise-record-v1",
  "ticker": "BHVN",
  "company": "Biohaven",
  "url": "https://www.orionbiotechai.com/company/BHVN",
  "generatedFrom": "founder-checked batch, as of 2026-10-12",
  "records": [
    {
      "chainId": "BHVN-P4",
      "program": "opakalim / RISE3 focal epilepsy · Topline results",
      "eventLabel": "Clinical results disclosure",
      "status": "Window open",
      "statusDefinition": "https://www.orionbiotechai.com/orion-methodology.html#promise-status-window-open",
      "firstStated": {
        "statement": "We expect to report topline results from RISE 3 in the second half of 2026.",
        "window": "in the second half of 2026",
        "documentType": "SEC Form 10-Q",
        "date": "2026-05-04",
        "dateBasis": "filing_date",
        "url": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000045/bhvn-20260331.htm"
      },
      "restatements": [
        {
          "kind": "Statement retained",
          "statement": "Topline results from the Phase 2/3 RISE3 trial in focal epilepsy remain on track for 2H 2026.",
          "window": "for 2H 2026",
          "documentType": "SEC Exhibit 99.1",
          "date": "2026-08-10",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm"
        },
        {
          "kind": "Statement retained",
          "statement": "with RISE3 trial topline results expected in 2H 2026.",
          "window": "2H 2026",
          "documentType": "Company press release",
          "date": "2026-08-26",
          "dateBasis": "company_release",
          "url": "https://ir.biohaven.com/news-releases/news-release-details/biohaven-and-sk-biopharmaceuticals-enter-strategic-global"
        },
        {
          "kind": "Statement retained",
          "statement": "with RISE3 trial topline results expected in 2H 2026.",
          "window": "2H 2026",
          "documentType": "SEC Exhibit 99.1",
          "date": "2026-08-26",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit991-biohavenandskbi.htm"
        },
        {
          "kind": "Statement retained",
          "statement": "topline data readout remains on timeline for the second half of 2026",
          "window": "for the second half of 2026",
          "documentType": "SEC Form 8-K",
          "date": "2026-09-10",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm"
        },
        {
          "kind": "Statement retained",
          "statement": "Dosing continues in BHV7000-303 and topline data remain on track for the second half of 2026.",
          "window": "for the second half of 2026",
          "documentType": "SEC Form 8-K",
          "date": "2026-09-10",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm"
        }
      ],
      "disclosure": null,
      "additionalDisclosures": [],
      "scopeNotes": [
        "The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.",
        "Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial.",
        "Additional source review: 2026-10-10. Earlier retained sources were reviewed on 2026-10-09; their original source-check dates and scopes are retained.",
        "ClinicalTrials.gov NCT06309966: acronym RISE 3; organization study ID BHV7000-303."
      ],
      "scopeSources": [
        {
          "date": "2026-08-13",
          "documentType": "Biohaven sponsor-submitted ClinicalTrials.gov record",
          "url": "https://clinicaltrials.gov/study/NCT06309966",
          "statement": null
        }
      ],
      "contextDisclosures": [
        {
          "kind": "Context disclosed",
          "documentType": "SEC Form 8-K",
          "date": "2026-09-10",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm",
          "eventDate": "2026-09-04",
          "eventLabel": "FDA partial clinical hold letter",
          "sourceLocator": "Item 8.01: paragraph beginning Thus, FDA and paragraph beginning BHV7000-303, one of two pivotal studies",
          "excerpts": [
            "partial clinical hold letter on September 4, 2026",
            "new patient enrollment only",
            "Dosing continues",
            "topline data remain on track",
            "second half of 2026"
          ]
        }
      ],
      "companyReleases": [
        {
          "date": "2026-08-26",
          "url": "https://ir.biohaven.com/news-releases/news-release-details/biohaven-and-sk-biopharmaceuticals-enter-strategic-global"
        },
        {
          "date": "2026-10-08",
          "url": "https://ir.biohaven.com/news-releases/news-release-details/biohaven-enters-strategic-licensing-agreement-ono-pharma"
        }
      ],
      "companySourceChecks": [
        {
          "url": "https://ir.biohaven.com/press-releases",
          "checkedDate": "2026-10-09",
          "label": "Company press release listing"
        }
      ],
      "secCheckedThrough": "2026-09-10",
      "secScope": "10-Q 5/4, 8-K 8/10, 8-K 8/26 quotes checked against originals. Later SEC filings not searched. Supplement reviewed 2026-10-10: selected 2026-09-10 SEC Form 8-K timing occurrences. This is not an exhaustive later-filing search.",
      "companyPrCheckedDate": "2026-10-09",
      "companyPrScope": "Company press releases page 1 checked on 10/9; Oct 8 release is BHV-1300, not RISE3.",
      "founderCheckedDate": "2026-10-10",
      "rowsShown": 1,
      "rowsTotal": 1,
      "citation": "Biohaven (BHVN) — opakalim / RISE3 focal epilepsy · Topline results: “in the second half of 2026” (SEC Form 10-Q 2026-05-04); statement retained “for 2H 2026” (2026-08-10); statement retained “2H 2026” (2026-08-26); statement retained “2H 2026” (2026-08-26); statement retained “for the second half of 2026” (2026-09-10); statement retained “for the second half of 2026” (2026-09-10). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000045/bhvn-20260331.htm | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm | https://ir.biohaven.com/news-releases/news-release-details/biohaven-and-sk-biopharmaceuticals-enter-strategic-global | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit991-biohavenandskbi.htm | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm",
      "corrections": [
        {
          "date": "2026-10-09",
          "what": "Display rule corrected — equivalent timing phrases (e.g., 'H2 2026' / 'second half of 2026') are now shown as Statement retained. Source quotes and status unchanged.",
          "why": "Equivalent timing notation is compared after normalization.",
          "evidence": "Founder approved the normalization correction and this exact public line in this chat on 2026-10-09.",
          "displayOnly": true
        },
        {
          "date": "2026-10-10",
          "what": "Added source-context excerpts from 2026-09-10 SEC Form 8-K.",
          "why": "Founder-requested context retained from the checked original filing.",
          "evidence": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm"
        },
        {
          "date": "2026-10-10",
          "what": "Added previously omitted 2026-09-10 SEC Form 8-K timing source.",
          "why": "Selected-source supplement following founder review; prior rows retained.",
          "evidence": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm"
        }
      ]
    }
  ]
}